Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Fasiglifam

Catalog No: tcsc0282

Available Sizes

Size: 2mg

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg

Size: 200mg

Specifications

CAS No:
1000413-72-8

Formula:
$C_{29}H_{32}O_7S$

Pathway:
GPCR/G Protein

Target:
GPR40

Purity / Grade:
>98%

Solubility:
DMSO : ≥ 128 mg/mL (243.98 mM)

Alternative Names:
TAK-875

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Observed Molecular Weight:
524.63

Product Description

Fasiglifam (TAK-875) is a potent, selective and orally bioavailable **GPR40** agonist with **EC_{50}** of 72 nM.

IC50 & Target: EC50: 72 nM (GPR40)

In Vitro: Fasiglifam (TAK-875) (0.01-10 μM) produces a concentration-dependent increase in intracellular IP production in CHO-hGPR40, with EC_{50} of 0.072 μM. Fasiglifam (TAK-875) (0.1-10 μM) dose-dependently augments intracellular IP production in CHO cells [1]. Fasiglifam (TAK-875) (3-30 μM) concentration-dependently augments $[Ca^{2+}]_i$. In the presence of 10 mM glucose, TAK-875 (0.001-10 μM) dose-dependently stimulats insulin secretion from INS-1 833/15 cells[2].

In Vivo: Fasiglifam (TAK-875) (10 mg/kg, p.o.) increases plasma insulin levels in ZDF rats. Fasiglifam (TAK-875) (30 mg/kg, p.o.) improves fasting hyperglycemia without affecting fasting normoglycemia. Fasiglifam (TAK-875) at 30 mg/kg, which is a 3- to 10-fold higher dose compared with the dose that improved glucose tolerance in diabetic rats, does not alter fasting glucose levels in SD rats with normal glucose homeostasis. Likewise, Fasiglifam (TAK-875) does not significantly alter insulin secretion in SD rats with normal fasting glucose levels [1].